vs

Side-by-side financial comparison of Cannae Holdings, Inc. (CNNE) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

Cannae Holdings, Inc. is the larger business by last-quarter revenue ($103.3M vs $75.5M, roughly 1.4× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -6.0%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $12.0M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -3.4%).

Cannae Holdings, Inc. is a diversified holding company that primarily invests in and operates businesses across multiple sectors including financial services, restaurant and hospitality, technology, and healthcare. Its core market is the United States, and it focuses on driving long-term stakeholder value through active portfolio management and strategic operational support for its portfolio companies.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

CNNE vs PBYI — Head-to-Head

Bigger by revenue
CNNE
CNNE
1.4× larger
CNNE
$103.3M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+33.7% gap
PBYI
27.7%
-6.0%
CNNE
More free cash flow
PBYI
PBYI
$2.4M more FCF
PBYI
$14.4M
$12.0M
CNNE
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-3.4%
CNNE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CNNE
CNNE
PBYI
PBYI
Revenue
$103.3M
$75.5M
Net Profit
$-93.0M
Gross Margin
15.2%
69.3%
Operating Margin
-23.3%
22.7%
Net Margin
-90.0%
Revenue YoY
-6.0%
27.7%
Net Profit YoY
-101.7%
EPS (diluted)
$-2.09
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNNE
CNNE
PBYI
PBYI
Q4 25
$103.3M
$75.5M
Q3 25
$106.9M
$54.5M
Q2 25
$110.2M
$52.4M
Q1 25
$103.2M
$46.0M
Q4 24
$109.9M
$59.1M
Q3 24
$113.9M
$80.5M
Q2 24
$118.0M
$47.1M
Q1 24
$110.7M
$43.8M
Net Profit
CNNE
CNNE
PBYI
PBYI
Q4 25
$-93.0M
Q3 25
$-68.4M
$8.8M
Q2 25
$-238.8M
$5.9M
Q1 25
$-113.0M
$3.0M
Q4 24
$-46.1M
Q3 24
$-13.6M
$20.3M
Q2 24
$-155.0M
$-4.5M
Q1 24
$-89.9M
$-4.8M
Gross Margin
CNNE
CNNE
PBYI
PBYI
Q4 25
15.2%
69.3%
Q3 25
17.1%
77.7%
Q2 25
17.6%
76.5%
Q1 25
11.8%
77.1%
Q4 24
16.4%
76.4%
Q3 24
18.3%
63.9%
Q2 24
21.9%
77.4%
Q1 24
14.9%
75.5%
Operating Margin
CNNE
CNNE
PBYI
PBYI
Q4 25
-23.3%
22.7%
Q3 25
-12.3%
17.6%
Q2 25
-55.3%
12.7%
Q1 25
-20.7%
8.7%
Q4 24
-20.0%
22.6%
Q3 24
-15.9%
27.4%
Q2 24
-19.5%
-4.6%
Q1 24
-36.7%
-5.3%
Net Margin
CNNE
CNNE
PBYI
PBYI
Q4 25
-90.0%
Q3 25
-64.0%
16.2%
Q2 25
-216.7%
11.2%
Q1 25
-109.5%
6.5%
Q4 24
-41.9%
Q3 24
-11.9%
25.2%
Q2 24
-131.4%
-9.6%
Q1 24
-81.2%
-11.0%
EPS (diluted)
CNNE
CNNE
PBYI
PBYI
Q4 25
$-2.09
$0.26
Q3 25
$-1.25
$0.17
Q2 25
$-3.93
$0.12
Q1 25
$-1.81
$0.06
Q4 24
$-0.75
$0.40
Q3 24
$-0.22
$0.41
Q2 24
$-2.49
$-0.09
Q1 24
$-1.27
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNNE
CNNE
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$182.0M
$97.5M
Total DebtLower is stronger
$70.8M
$22.7M
Stockholders' EquityBook value
$1.0B
$130.3M
Total Assets
$1.3B
$216.3M
Debt / EquityLower = less leverage
0.07×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNNE
CNNE
PBYI
PBYI
Q4 25
$182.0M
$97.5M
Q3 25
$233.8M
$94.4M
Q2 25
$66.7M
$96.0M
Q1 25
$126.2M
$93.2M
Q4 24
$131.5M
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
CNNE
CNNE
PBYI
PBYI
Q4 25
$70.8M
$22.7M
Q3 25
$68.6M
$34.0M
Q2 25
$168.4M
$45.3M
Q1 25
$170.6M
$56.7M
Q4 24
$181.0M
$68.0M
Q3 24
$181.2M
$79.3M
Q2 24
$78.2M
$90.7M
Q1 24
$79.3M
$102.0M
Stockholders' Equity
CNNE
CNNE
PBYI
PBYI
Q4 25
$1.0B
$130.3M
Q3 25
$1.2B
$115.3M
Q2 25
$1.4B
$104.7M
Q1 25
$1.7B
$97.1M
Q4 24
$1.8B
$92.1M
Q3 24
$1.9B
$71.1M
Q2 24
$1.9B
$48.5M
Q1 24
$2.3B
$51.0M
Total Assets
CNNE
CNNE
PBYI
PBYI
Q4 25
$1.3B
$216.3M
Q3 25
$1.5B
$202.9M
Q2 25
$1.8B
$194.9M
Q1 25
$2.1B
$196.2M
Q4 24
$2.2B
$213.3M
Q3 24
$2.3B
$220.7M
Q2 24
$2.2B
$205.0M
Q1 24
$2.6B
$214.1M
Debt / Equity
CNNE
CNNE
PBYI
PBYI
Q4 25
0.07×
0.17×
Q3 25
0.06×
0.30×
Q2 25
0.12×
0.43×
Q1 25
0.10×
0.58×
Q4 24
0.10×
0.74×
Q3 24
0.10×
1.12×
Q2 24
0.04×
1.87×
Q1 24
0.03×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNNE
CNNE
PBYI
PBYI
Operating Cash FlowLast quarter
$16.0M
$14.4M
Free Cash FlowOCF − Capex
$12.0M
$14.4M
FCF MarginFCF / Revenue
11.6%
19.1%
Capex IntensityCapex / Revenue
3.9%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-28.5M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNNE
CNNE
PBYI
PBYI
Q4 25
$16.0M
$14.4M
Q3 25
$-21.6M
$9.7M
Q2 25
$-21.6M
$14.1M
Q1 25
$9.1M
$3.6M
Q4 24
$-12.0M
$15.6M
Q3 24
$-31.9M
$11.0M
Q2 24
$-10.2M
$1.0M
Q1 24
$-36.0M
$11.2M
Free Cash Flow
CNNE
CNNE
PBYI
PBYI
Q4 25
$12.0M
$14.4M
Q3 25
$-24.1M
$9.7M
Q2 25
$-23.6M
$14.1M
Q1 25
$7.2M
$3.6M
Q4 24
$-14.4M
$15.6M
Q3 24
$-33.6M
$11.0M
Q2 24
$-11.8M
$1.0M
Q1 24
$-37.3M
FCF Margin
CNNE
CNNE
PBYI
PBYI
Q4 25
11.6%
19.1%
Q3 25
-22.5%
17.7%
Q2 25
-21.4%
26.8%
Q1 25
7.0%
7.7%
Q4 24
-13.1%
26.4%
Q3 24
-29.5%
13.7%
Q2 24
-10.0%
2.1%
Q1 24
-33.7%
Capex Intensity
CNNE
CNNE
PBYI
PBYI
Q4 25
3.9%
0.0%
Q3 25
2.3%
0.0%
Q2 25
1.8%
0.0%
Q1 25
1.8%
0.1%
Q4 24
2.2%
0.0%
Q3 24
1.5%
0.0%
Q2 24
1.4%
0.0%
Q1 24
1.2%
0.0%
Cash Conversion
CNNE
CNNE
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CNNE
CNNE

Reportable Segment Aggregation Before Other Operating Segment$94.9M92%
Other Operating Revenue$8.4M8%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons